Latest news with #clinicaldevelopment
Yahoo
a day ago
- Business
- Yahoo
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the . Analysts at H.C. Wainwright have reiterated their Buy rating on Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) while maintaining a price target of $2, implying an upside of over 900%. This overwhelming optimism stems from the company's comprehensive portfolio update just a few days ago. While focusing on the clinical development of its leading candidate, NGC-Cap, Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) has also started to initiate an adaptive pivotal Phase 3 study for PCS499 to address underserved kidney areas based on preliminary positive results and FDA approval of surrogate endpoints. With such a vision in mind, there is no doubt the company can actually exceed analyst expectations. A syringe filled with a biopharmaceutical drug product on a light blue background. On top of that, Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) has entered into a binding term sheet with privately held Intact Therapeutics, enabling it to receive $454 million in milestone payments, a 12% royalty on future sales, and a 3.5% equity stake in Intact. The exclusivity of its PCS12852 prokinetic agent for gastroparesis and other gastrointestinal motility disorders positions PCSA well to lead the market. Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a Maryland-based clinical-stage biopharmaceutical company that develops chemotherapy drugs to enhance the efficacy of cancer treatment. Incorporated in 2017, the company adopts a 'Regulatory Science Approach' to more effectively lead its pipeline programs. While we acknowledge the potential of PCSA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 days ago
- Business
- Yahoo
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Morgan Stanley assumed coverage of the company's stock with an 'Equal Weight' rating and a price objective of $5, as reported by The Fly. As per the analyst, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s stock witnessed volatility because of a combination of macroeconomic factors, underperformance on initial clinical results, and uncertainty related to the valuation and revenue drivers. Furthermore, the recent pipeline prioritization and stage of clinical development for the proprietary pipeline tend to leave numerous open questions on valuation, added the firm analyst. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. However, as part of the business combination with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been proactively streamlining its portfolio, platform, and operations, making trade-offs to emphasize resources on programs having the strongest scientific rationale and highest potential for near and long-term impact. In Q1 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s total revenue, consisting mainly of revenue from collaboration agreements, came in at $15 million as compared to $14 million for Q1 2024. This was because of the timing of projects from its Sanofi, Roche and Merck KGaA, Darmstadt, Germany collaborations. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Morgan Stanley assumed coverage of the company's stock with an 'Equal Weight' rating and a price objective of $5, as reported by The Fly. As per the analyst, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s stock witnessed volatility because of a combination of macroeconomic factors, underperformance on initial clinical results, and uncertainty related to the valuation and revenue drivers. Furthermore, the recent pipeline prioritization and stage of clinical development for the proprietary pipeline tend to leave numerous open questions on valuation, added the firm analyst. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. However, as part of the business combination with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been proactively streamlining its portfolio, platform, and operations, making trade-offs to emphasize resources on programs having the strongest scientific rationale and highest potential for near and long-term impact. In Q1 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s total revenue, consisting mainly of revenue from collaboration agreements, came in at $15 million as compared to $14 million for Q1 2024. This was because of the timing of projects from its Sanofi, Roche and Merck KGaA, Darmstadt, Germany collaborations. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Actithera draws new investors to radiopharma drug pitch
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Actithera, a radiopharmaceutical drugmaker based in Oslo, Norway and Cambridge, Massachusetts, has raised just under $76 million in Series A venture financing to build out its cancer drug pipeline. In a Wednesday statement, the biotechnology company said it would use the new funds to advance into clinical development an experimental treatment targeting what are known as fibroblast activation proteins. M Ventures, which helped found the company in 2021, co-led the Series A round with Hadean Ventures, Sofinnova Partners and 4BIO Capital. Five other firms also participated. Radiopharmaceuticals offer a better way to target tumor-killing radiation more precisely to cancerous cells and, accordingly, they've drawn rising interest from drugmakers. The technology works by attaching a radioisotope to a targeting compound via a specially engineered 'linker' molecule. While radiopharmaceuticals have been around for years — Bayer's Xofigo was approved in the U.S. in 2013 — the field has taken off since the success of Novartis' prostate cancer treatment Pluvicto. The drug earned Novartis more than $1.3 billion in 2025, giving the industry a glimpse of radiopharmaceuticals' sales potential. Other large companies, like Bristol Myers Squibb and Eli Lilly, have entered the field with acquisitions of earlier-stage public biotechs. Private radiopharma companies, meanwhile, drew more than $1.1 billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive. Actithera is designing its cancer drugs so they can stay in a tumor for longer by binding tightly to proteins that help a tumor grow. Founded by Andreas Goutopoulos, a veteran of Merck KGaA's U.S. subsidiary EMD Serono Inc., the biotech is focused first on an enzyme called fibroblast activation protein, or FAP. The protein is expressed on cells that form connective tissue, but in cancer can support tumor growth. Actithera aims to eliminate those proteins and cancer-associated fibroblasts in 'a cross-fire effect that kills nearby tumor cells,' Goutopoulos said. 'It's a way to dismantle a critical barrier to immune and therapeutic access,' he wrote in an email to BioPharma Dive. Radiopharmaceuticals can be tricky to develop. Manufacturing is complex and expensive, and in response, companies like Novartis have opened dedicated production facilities. The isotope they contain also degrades over time, making the logistics of their delivery critical. Actithera is one of many up-and-coming biotechs looking to follow Novartis' lead. Some of those, including Novartis and Ratio Therapeutics, are also targeting FAP. Actithera has not disclosed which cancers it's targeting with its therapies. The company is 'preparing for clinical development in 2026' across multiple indications, Goutopoulos said. 'Actithera stands out as one of the most thoughtfully constructed radiopharma platforms we've seen, combining smart molecular design with a deep understanding of tumor biology and clinical need,' Roger Franklin, a partner at Hadean Ventures, said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
AB Science announces the successful completion of a EUR 1.925 million private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 1.925 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 1,645,302 new ordinary shares in the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 2.47% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 2,41% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on July 7, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 7, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.17 (including share issue premium), representing a facial discount of 24.36% (i.e. EUR 0.38) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. July 7, 4 and 3, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 18.84% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.78 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 1,645,302 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 2.93 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of July 7, 2025, is equal to EUR 0.4392 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to July 14, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 681,937.55 (or EUR 698,390.57 in the event of exercise of all BSAs). It will be comprised of 61,431,076 ordinary shares (or of 63,076,378 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.98% on a non-diluted basis and 0.79% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on July 10, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 7, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. July 7, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). July 8, 2025 Publication of this press of the Information Document. July 10, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. July 10, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. July 14, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - AK July 2025 Press Release VEng VFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
